Mar 05, 2021 09:08 AM (GMT+8) · EqualOcean
On March 5, 2021, signet therapeutics, a cancer innovative targeted drug R & D company based on disease model, announced that it had overfulfilled the angel round financing of about 60 million yuan. This round of investment is led by Tiantu investment, followed by many investment institutions such as Lihe venture capital, Jingtai technology and Yunjiu capital. This round of financing will be used for the expansion of the R & D team and the rapid advancement of the existing pipeline to the clinical stage, as well as the screening of new target lead compounds.